Key result
Ezetimibe is linked to reduced AF burden through enhanced mitochondrial calcium uptake.
Why the study?
Does enhancing mitochondrial calcium uptake with ezetimibe reduce arrhythmogenic events and atrial fibrillation burden?
Does enhancing mitochondrial calcium uptake with ezetimibe reduce arrhythmogenic events and atrial fibrillation burden?
Impaired mitochondrial calcium uptake due to microtubule destabilization contributes to atrial fibrillation, and enhancing this uptake with ezetimibe may reduce arrhythmogenic events and AF burden.
BACKGROUND: Mitochondrial calcium (Ca 2+ ) is a key regulator of cardiac energetics by stimulating the tricarboxylic acid cycle during elevated workload. Atrial fibrillation (AF) is associated with a reduction in cytosolic Ca 2+ transient amplitude, but its effect on mitochondrial Ca 2+ handling and cellular redox state has not been explored in AF. METHODS: Cardiac myocytes isolated from patient-derived right atrial biopsies were subjected to workload transitions using patch-clamp stimulation and β-adrenergic stimulation (isoproterenol). In conjunction, NAD(P)H/flavin adenine dinucleotide autofluorescence, cytosolic and mitochondrial [Ca 2+ ] were monitored using epifluorescence microscopy. Sarcoplasmic reticulum and mitochondria were imaged using electron tomography and stimulated emission depletion microscopy. The effects of the mitochondrial Ca 2+ uptake enhancer ezetimibe on proarrhythmic activity in atrial myocytes and on AF burden in patients were investigated. RESULTS: Mitochondrial Ca 2+ accumulation during increased workload was blunted in AF, and was associated with impaired regeneration of nicotinamide adenine dinucleotide and flavin adenine dinucleotide. Nanoscale imaging revealed spatial disorganization of sarcoplasmic reticulum and mitochondria, associated with microtubule destabilization. This was confirmed in human induced pluripotent stem cell–derived myocytes, where nocodazole treatment displaces mitochondria and increases proarrhythmic Ca 2+ sparks, which were rescued by MitoTEMPO. Ezetimibe also reduced the occurrence of arrhythmogenic Ca 2+ release events both in AF myocytes and nocodazole-treated human induced pluripotent stem cell–derived cardiac myocytes. Retrospective patient analysis also revealed a reduced AF burden in patients on ezetimibe treatment. CONCLUSIONS: Mitochondrial Ca 2+ uptake and accumulation are impaired in atrial myocytes from patients with AF. The disturbed spatial association between sarcoplasmic reticulum and mitochondria driven by destabilized microtubules may underlie impaired Ca 2+ transfer in AF. Enhancing mitochondrial Ca 2+ uptake potentially protects against arrhythmogenic events.
No takes yet. Share an insight, caveat, or question.
Pronto et al. (2025) studied Atrial fibrillation. Ezetimibe was evaluated on Atrial fibrillation burden and mitochondrial calcium accumulation. Mitochondrial calcium uptake is impaired in atrial myocytes from patients with atrial fibrillation, and retrospective analysis suggests ezetimibe treatment is associated with reduced AF burden.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: